Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients (SECOX)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01245582
First received: November 19, 2010
Last updated: November 8, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: August 2015
  Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)